YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis

Shen,Haibo; Zheng,Enkuo; Yang,Zhenhua; Yang,Minglei; Xu,Xiang; Zhou,Yinjie; Ni,Junjun; Li,Rui; Zhao,Guofang

doi:10.3892/ol.2020.11560

YRDC is upregulated in non‑small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis

Authors:
- Haibo Shen
- Enkuo Zheng
- Zhenhua Yang
- Minglei Yang
- Xiang Xu
- Yinjie Zhou
- Junjun Ni
- Rui Li
- Guofang Zhao
View Affiliations

Affiliations: Cardiothoracic Surgery Department, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, P.R. China
Published online on: April 21, 2020 https://doi.org/10.3892/ol.2020.11560
Pages: 43-52
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer‑associated mortality worldwide. yrdC N6‑threonylcarbamoltransferase domain containing protein (YRDC) has been demonstrated to be involved in the formation of threonylcarbamoyladenosine in transfer ribonucleic acid. However, the molecular mechanisms underlying NSCLC progression remain largely unclear. The present study revealed that YRDC was upregulated in NSCLC samples compared with adjacent non‑cancerous tissues by analyzing datasets obtained from the Gene Expression Omnibus and The Cancer Genome Atlas. Higher expression of YRDC was associated with overall survival time and disease‑free survival time in patients with NSCLC, particularly in lung adenocarcinoma. Furthermore, knockdown of YRDC in NSCLS cell lines significantly suppressed cell growth and cell colony formation in vitro. Additionally, the results demonstrated that silencing of YRDC induced apoptosis of A549 cells. Then, the protein‑protein interaction networks associated with yrdC N6‑threonylcarbamoltransferase domain containing protein (YRDC) in NSCLC were subsequently constructed to investigate the potential molecular mechanism underlying the role of YRDC in NSCLC. The results revealed that YRDC was involved in the regulation of spliceosomes, ribosomes, the p53 signaling pathway, proteasomes, the cell cycle and DNA replication. The present study demonstrated that YRDC may serve as a novel biomarker for the prognosis prediction and treatment of NSCLC.

View Figures

View References

1	Qiao WL, Shi BW, Han YD, Tang HM, Lin J, Hu HY and Lin Q: Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 15:8796–8804. 2018.PubMed/NCBI
2	Su Q, Sun YP, Liu YH, Li Z, Yang HY, Sun ZG, Cao BW and Jia JH: Prognostic factors in older patients with advanced non-small cell lung cancer in China. Tumori. 100:69–74. 2014. View Article : Google Scholar : PubMed/NCBI
3	Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, et al: A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol. 12:913–924. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zheng X, Cheng M, Fu B, Fan X, Wang Q, Yu X, Sun R, Tian Z and Wei H: Targeting LUNX inhibits non-small cell lung cancer growth and metastasis. Cancer Res. 75:1080–1090. 2015. View Article : Google Scholar : PubMed/NCBI
5	McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH, et al: TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res. 75:415–425. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yue Y, Liu J and He C: RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 29:1343–1355. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kang BI, Miyauchi K, Matuszewski M, D'Almeida GS, Rubio MAT, Alfonzo JD, Inoue K, Sakaguchi Y and Suzuki T, Sochacka E and Suzuki T: Identification of 2-methylthio cyclic N6-threonylcarbamoyladenosine (ms2ct6A) as a novel RNA modification at position 37 of tRNAs. Nucleic Acids Res. 45:2124–2136. 2017. View Article : Google Scholar : PubMed/NCBI
8	Vaidyanathan PP, AlSadhan I, Merriman DK, Al-Hashimi HM and Herschlag D: Pseudouridine and N⁶-methyladenosine modifications weaken PUF protein/RNA interactions. RNA. 23:611–618. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zhao BS and He C: Pseudouridine in a new era of RNA modifications. Cell Res. 25:153–154. 2015. View Article : Google Scholar : PubMed/NCBI
10	Wang CY, Lin MH and Su HT: A method for measuring RNA N 6-methyladenosine modifications in cells and tissues. J Vis Exp. 5:2016.
11	Yu J, Chen M, Huang H, Zhu J, Song H, Zhu J, Park J and Ji SJ: Dynamic m6A modification regulates local translation of mRNA in axons. Nucleic Acids Res. 46:1412–1423. 2018. View Article : Google Scholar : PubMed/NCBI
12	Thiaville PC, El Yacoubi B, Köhrer C, Thiaville JJ, Deutsch C, Iwata-Reuyl D, Bacusmo JM, Armengaud J, Bessho Y, Wetzel C, et al: Essentiality of threonylcarbamoyladenosine (t(6)A), a universal tRNA modification, in bacteria. Mol Microbiol. 98:1199–1221. 2015. View Article : Google Scholar : PubMed/NCBI
13	El Yacoubi B, Lyons B, Cruz Y, Reddy R, Nordin B, Agnelli F, Williamson JR, Schimmel P, Swairjo MA and de Crécy-Lagard V: The universal YrdC/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA. Nucleic Acids Res. 37:2894–2909. 2009. View Article : Google Scholar : PubMed/NCBI
14	Huang B, Zhai W, Hu G, Huang C, Xie T, Zhang J and Xu Y: MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC. Am J Transl Res. 8:4705–4715. 2016.PubMed/NCBI
15	Cui F, Hu J, Ning S, Tan J and Tang H: Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer. Prostate. 78:1299–1310. 2018. View Article : Google Scholar : PubMed/NCBI
16	Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli N: Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 34:2846–2855. 2015. View Article : Google Scholar : PubMed/NCBI
17	Nagy Á, Lánczky A, Menyhárt O and Győrffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 8:92272018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Zhu T, An S, Choy MT, Zhou J, Wu S, Liu S, Liu B, Yao Z, Zhu X, Wu J and He Z: LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression. J Cell Mol Med. 23:1852–1864. 2019. View Article : Google Scholar : PubMed/NCBI
20	Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R and Fárez-Vidal ME: Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer. 129:355–364. 2011. View Article : Google Scholar : PubMed/NCBI
21	Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC and Chuang EY: Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev. 19:2590–2597. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 5:e103122010. View Article : Google Scholar : PubMed/NCBI
23	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
24	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
25	Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
26	Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and Galon J: ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
27	Viktorsson K and Lewensohn R: Apoptotic signaling pathways in lung cancer. J Thorac Oncol. 2:175–179. 2007. View Article : Google Scholar : PubMed/NCBI
28	Liao M: Some features of lung cancer in China. Lung Cancer. 10:107–116. 1993. View Article : Google Scholar : PubMed/NCBI
29	Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan W, Li J, Zhan Y, Wang L, Zhang S, et al: Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol. 12:648–658. 2018. View Article : Google Scholar : PubMed/NCBI
30	Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, et al: Polycomb repressive complex 2 is a barrier to KRAS-Driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell. 29:17–31. 2016. View Article : Google Scholar : PubMed/NCBI
31	Ludlow AT, Wong MS, Robin JD, Batten K, Yuan L, Lai TP, Dahlson N, Zhang L, Mender I, Tedone E, et al: NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun. 9:31122018. View Article : Google Scholar : PubMed/NCBI
32	Kaczanowska M and Rydén-Aulin M: The YrdC protein-a putative ribosome maturation factor. Biochim Biophys Acta. 1727:87–96. 2005. View Article : Google Scholar : PubMed/NCBI
33	Lemiere S, Azar R, Belloc F, Gürsel D, Pyronnet S, Bikfalvi A and Auguste P: Overexpression of high molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and protein translation. Exp Cell Res. 314:3701–3711. 2008. View Article : Google Scholar : PubMed/NCBI
34	Brewer JW, Hendershot LM, Sherr CJ and Diehl JA: Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci USA. 96:8505–8510. 1999. View Article : Google Scholar : PubMed/NCBI
35	Nakamura H and Nishimura T: History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer. Surg Today. 47:1037–1059. 2017. View Article : Google Scholar : PubMed/NCBI
36	Lin Q, Chen XY, Liu WF, Zhu PW, Shi WQ, Li B, Yuan Q, Min YL, Liu JM and Shao Y: Diagnostic value of CA-153 and CYFRA 21-1 in predicting intraocular metastasis in patients with metastatic lung cancer. Cancer Med. Jun 20–2019.(Epub ahead of print).
37	Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B and Zhang X: Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer. 66:245–249. 2009. View Article : Google Scholar : PubMed/NCBI
38	Yu Y, Yang A, Hu S, Zhang J and Yan H: Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas. Clin Respir J. 7:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
39	Niklinska W, Burzykowski T, Chyczewski L and Niklinski J: Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): Association with p53 gene mutation and prognosis. Lung Cancer. 34 (Suppl 2):S59–S64. 2001. View Article : Google Scholar : PubMed/NCBI
40	Li S, Zhao H, Li J, Zhang A and Wang H: Downregulation of long non-coding RNA LET predicts poor prognosis and increases Notch signaling in non-small cell lung cancer. Oncotarget. 9:1156–1168. 2017.PubMed/NCBI
41	Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM, Xia R, Shu YQ and De W: Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 6:e16652015. View Article : Google Scholar : PubMed/NCBI
42	He X, Liu Z, Su J, Yang J, Yin D, Han L, De W and Guo R: Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer. Tumour Biol. 37:9503–9510. 2016. View Article : Google Scholar : PubMed/NCBI